Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.59 |
| ▸ | ACHE | P22303 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | GLA | P06280 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | CASP1 | P29466 | 2/20 | 0.50 |
| ▸ | CASP7 | P55210 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | NQO2 | P16083 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4492054 | 0.77 | ADORA2A (0.47) | ADORA2AACHEKDM4EALDH1A1GLA | |
| SCHEMBL14929703 | 0.76 | ADORA2A (0.60) | ADORA2AACHEKDM4EALDH1A1GLA | |
| SCHEMBL3833630 | 0.76 | ADORA2A (0.56) | ADORA2AACHEKDM4EALDH1A1GLA | |
| SCHEMBL6276708 | 0.76 | ADORA2A (0.60) | ADORA2AKDM4EALDH1A1GLAHPGD | |
| SCHEMBL4913937 | 0.72 | ADORA2A (0.70) | ADORA2AACHEKDM4EALDH1A1GLA | |
| SCHEMBL15101407 | 0.72 | GRM2 (0.50) | KDM4EALDH1A1RAB9AKMT2ANPC1 | |
| SCHEMBL12491743 | 0.71 | CYP1A1 (0.56) | ADORA2AACHEKDM4EALDH1A1GLA | |
| SCHEMBL6045368 | 0.71 | KDM4E (0.53) | KDM4EALDH1A1CASP1CASP7SMN1; SMN2 | |
| SCHEMBL6341548 | 0.70 | ALDH1A1 (0.57) | KDM4EALDH1A1HPGDCASP1SMN1; SMN2 | |
| SCHEMBL28312221 | 0.69 | ALDH1A1 (0.50) | ADORA2AACHEKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200147069-A1 | Compounds for The Reduction of The Deleterious Activity of Extended Nucleotide Repeat Containing Genes | THE BOARD OF TRUSTEES OF LELAND STANFORD JUNIOR UNIVERSITY | 2020-05-14 | — | — | US | disclosed |
| EP-3641758-A1 | COMPOUNDS FOR THE REDUCTION OF THE DELETERIOUS ACTIVITY OF EXTENDED NUCLEOTIDE REPEAT CONTAINING GENES | The Board of Trustees of the Leland Stanford Junior University (US) | 2020-04-29 | — | — | EP | disclosed |
| CN-110996942-A | Compounds for reducing the deleterious activity of genes containing extended nucleotide repeats | 小利兰.斯坦福大学托管委员会 | 2020-04-10 | — | — | CN | disclosed |
| WO-2018236910-A1 | COMPOUNDS FOR THE REDUCTION OF THE DELETERIOUS ACTIVITY OF EXTENDED NUCLEOTIDE REPEAT CONTAINING GENES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2018-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200147069-A1 | Compounds for The Reduction of The Deleterious Activity of Extended Nucleotide Repeat Containing Genes | NSUN2, RNMT, RRM2B | ADORA2A 1259/4885ACHE 3375/4885KDM4E 3306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.